TABLE 1.
Demographic data, underlying diagnosis, clinical features, therapy received, and outcome of 47 patients with SARS‐CoV‐2 confirmed infection
| Characteristics | N | |
|---|---|---|
| Age | 47 | |
| Mean (standard deviation) | 8.2 (4.7) | |
| 1 year or less | 6 (13%) | |
| 2‐5 years | 9 (19%) | |
| 6‐10 years | 15 (32%) | |
| 11‐14 years | 13 (28%) | |
| 15‐18 years | 4 (8%) | |
| Sex | 47 | |
| Male | 34 (72%) | |
| Female | 13 (28%) | |
| Type | 47 | |
| Nonmalignant hemopathy a | 6 (13%) | |
| Solid tumor | 14 (30%) | |
| Leukemia/lymphoma non‐HSCT | 19 (40%) | |
| Post‐HSCT | 8 (17%) | |
| Phase | 41 | |
| First line | 33 (80%) | |
| Relapse | 8 (20%) | |
| Severity of illness | 47 | |
| Asymptomatic | 12 (26%) | |
| Mild | 24 (51%) | |
| Serious | 7 (15%) | |
| Critical | 4 (8%) | |
| Radiological image performed | 47 | |
| Yes | 37 (79%) | |
| No | 10 (21%) | |
| When performed: | 37 | |
| Normal | 25 (68%) | |
| Unilateral pneumonia | 6 (16%) | |
| Bilateral pneumonia | 6 (16%) | |
| Need for hospitalization | 47 | |
| Hospital care | 32 (77%) | |
| Critical care (ICU) | 4 (8%) | |
| Respiratory support | ||
| Conventional oxygen therapy | 47 | |
| Yes | 8 (17%) | |
| No | 39 (83%) | |
| High‐flow/noninvasive ventilation | 47 | |
| Yes | 3 (6%) | |
| No | 44 (10%) | |
| Mechanical ventilation | 47 | |
| Yes | 2 (4%) | |
| No | 45 (96%) | |
| Treatment | ||
| Hydroxychloroquine | 47 | |
| Yes | 23 (49%) | |
| No | 24 (51%) | |
| Antiviral | 47 | |
| Yes | 9 (19%) | |
| No | 38 (81%) | |
| Monoclonal antibody | 47 | |
| Yes | 6 (13%) | |
| No | 41 (87%) | |
| Interruption of baseline treatment: | 46 | |
| Yes | 22 (48%) | |
| No | 24 (52%) | |
| Clinical evolution | 47 | |
| Alive and resolved | 31 (66%) | |
| Alive, with active infection | 15 (32%) | |
| Exitus | 1 (2%) |
a
Autoimmune hemolytic anemia (one patient), sickle cell disease (one patient), bone marrow failure (2 patients), primary immune thrombocytopenia (one patient), hemophagocytic lymphohistiocytosis (one patient).
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.